Terms: = Lung cancer AND WFDC2, EDDM4, HE4, WAP5, dJ461P17.6 AND Treatment
15 results:
1. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract] [Full Text] [Related]
2. Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and he4 tumor markers.
Canki E; Schuurbiers MM; Linders TC; Korse CM; van den Heuvel MM; van Herwaarden AE; van Rossum HH
Tumour Biol; 2024; 46(s1):S15-S25. PubMed ID: 37302060
[TBL] [Abstract] [Full Text] [Related]
3. Development of exploratory algorithms to aid in risk of malignancy prediction of indeterminate pulmonary nodules.
Jeanblanc N; Jackson L; Gawel S; Brophy S; Vaidya S; Syed S; Davis GJ; Borgia JA
Clin Chim Acta; 2022 Oct; 535():197-202. PubMed ID: 36087784
[TBL] [Abstract] [Full Text] [Related]
4. Circulating biomarkers for monitoring therapy response and detection of disease progression in lung cancer patients.
de Kock R; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; van Dongen-Schrover C; Genet S; Brunsveld L; Scharnhorst V; Deiman B
Cancer Treat Res Commun; 2021; 28():100410. PubMed ID: 34107412
[TBL] [Abstract] [Full Text] [Related]
5. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of serum human epididymis protein 4 in patients with relapsing-remitting multiple sclerosis.
Adamczyk B; Partyka R; Adamczyk-Sowa M; Wierzbicki K; Sowa P; Kokocińska D
Adv Clin Exp Med; 2020 Aug; 29(8):943-948. PubMed ID: 32790249
[TBL] [Abstract] [Full Text] [Related]
7. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma.
Isaksson S; Jönsson P; Monsef N; Brunnström H; Bendahl PO; Jönsson M; Staaf J; Planck M
PLoS One; 2017; 12(10):e0186284. PubMed ID: 29049328
[TBL] [Abstract] [Full Text] [Related]
8. Preparation and characterization of a high-affinity monoclonal antibody against human epididymis protein-4.
Shen Y; Wang Y; Jiang X; Lu L; Wang C; Luo W; Zhang Y; Li P; Du Z; Dai T; Wu C; Fang A; Yao Y; Peng Q; Yang J
Protein Expr Purif; 2018 Jan; 141():44-51. PubMed ID: 28928083
[TBL] [Abstract] [Full Text] [Related]
9. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell lung cancers.
Li BT; Lou E; Hsu M; Yu HA; Naidoo J; Zauderer MG; Sima C; Johnson ML; Daras M; DeAngelis LM; Fleisher M; Kris MG; Azzoli CG
PLoS One; 2016; 11(1):e0146063. PubMed ID: 26730601
[TBL] [Abstract] [Full Text] [Related]
10. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract] [Full Text] [Related]
11. Serum he4: An Independent Prognostic Factor in Non-Small Cell lung cancer.
Lamy PJ; Plassot C; Pujol JL
PLoS One; 2015; 10(6):e0128836. PubMed ID: 26030627
[TBL] [Abstract] [Full Text] [Related]
12. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.
Lou E; Johnson M; Sima C; Gonzalez-Espinoza R; Fleisher M; Kris MG; Azzoli CG
Cancer Biomark; 2014; 14(4):207-14. PubMed ID: 24934363
[TBL] [Abstract] [Full Text] [Related]
13. Human epididymis protein 4 (he4) in benign and malignant diseases.
Hertlein L; Stieber P; Kirschenhofer A; Krocker K; Nagel D; Lenhard M; Burges A
Clin Chem Lab Med; 2012 Dec; 50(12):2181-8. PubMed ID: 23093276
[TBL] [Abstract] [Full Text] [Related]
14. Serum he4 as a diagnostic and prognostic marker for lung cancer.
Iwahori K; Suzuki H; Kishi Y; Fujii Y; Uehara R; Okamoto N; Kobayashi M; Hirashima T; Kawase I; Naka T
Tumour Biol; 2012 Aug; 33(4):1141-9. PubMed ID: 22373583
[TBL] [Abstract] [Full Text] [Related]
15. Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women.
Okamoto J; Onda M; Hirata T; Miyamoto S; Akaishi J; Mikami I; Hirai K; Haraguchi S; Koizumi K; Shimizu K
Gend Med; 2006 Sep; 3(3):223-35. PubMed ID: 17081955
[TBL] [Abstract] [Full Text] [Related]
